ArticleJACC. Advances2026
The Burden of Cardiovascular Disease in Lymphoma Survivors: A Population-Based Matched Cohort Study.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) is a leading cause of morbidity in lymphoma survivors, yet contemporary data on CVD risk in survivors are limited.
objectivesThis study assessed the hazard and absolute incidence of CVD in lymphoma survivors relative to cancer-free controls and evaluated temporal risks changes.
methodsWe conducted a population-based matched cohort study of adults diagnosed with lymphoma in Ontario, Canada (2007-2018), matched 1:1 to cancer-free controls by age and sex. The primary outcome was CVD hospitalization, with follow-up through March 2024. Cause-specific hazard models accounted for death as a competing risk, and cumulative incidence functions assessed absolute risk. We tested the significance of an interaction term with calendar year to test for changes in CVD incidence between 2007 to 2010, 2011 to 2014, and 2015 to 2018.
resultsAmong 36,334 lymphoma survivors (median age 65; 45% female), the average adjusted HR for CVD hospitalization was 1.58 (95% CI: 1.52-1.64) compared to cancer-free controls; this HR was comparable to cardiovascular risk factors such as hypertension. The HR was highest in the first-year post-diagnosis but remained elevated for at least 10 years. The absolute difference in CVD risk between lymphoma survivors and controls at 5 years doubled from 1.1% (95% CI: 0.3%-1.9%) in 2007-2010 to 2.3% (95% CI: 1.6%-3.0%) in 2015-2018 (P = 0.02).
conclusionsLymphoma survivors faced a persistently increased incidence of CVD compared to cancer-free individuals, and the absolute difference widened over the study period. The temporal risk patterns support current cardio-oncology guidelines recommending front-loaded and longitudinal cardiovascular surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.